Schizophrenia: instability in norepinephrine, serotonin, and gamma-aminobutyric acid systems. (Q39514501)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3042667%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

review article

1 reference

title

Schizophrenia: instability in norepinephrine, serotonin, and gamma-aminobutyric acid systems (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3042667%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

Schizophrenia: Instability in Norepinephrine, Serotonin, and γ-Aminobutyric Acid Systems (English)

0 references

0 references

1 reference

0 references

Joel Gelernter

1

0 references

Daniel P. van Kammen

series ordinal

2

object named as

Daniel P. van Kammen

0 references

author name string

Gelernter J

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3042667%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

van Kammen DP

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3042667%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

publication date

1 January 1988

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3042667%20AND%20SRC:MED&resulttype=core&format=json

International Review of Neurobiology

9 October 2019

1988

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3042667%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3042667%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

page(s)

309-347

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3042667%20AND%20SRC:MED&resulttype=core&format=json

Neuropeptide Y distribution in human brain

9 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Diazepam-binding inhibitor: a neuropeptide located in selected neuronal populations of rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Norepinephrine-dopamine interactions and behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Serotonin uptake by blood platelets of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Effects of chlorpromazine on serotonin uptake in blood platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Further studies with propranolol in psychotic patients. Relation to initial psychiatric state, urinary catecholamines and 3-methoxy-4-hydroxyphenylglycol excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Low-dose propranolol in tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

High dose diazepam in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

The effect of propranolol treatment in shizophrenia on CSF amine metabolites and prolactin

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Neurotransmitter Receptors in Frontal Cortex of Schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

CSF monoamine metabolites in depression and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Cerebrospinal fluid and plasma monoamines and their metabolites in euthymic bipolar patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Brain Norepinephrine and Dopamine in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

5-Hydroxyindoleacetic acid (5 HIAA) and homovanillic acid (HVA) following probenecid in acute psychotic patients treated with phenothiazines

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

CSF GABA in psychotic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Central catecholamines, cognitive impairment, and affective state in elderly schizophrenics and controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

γ-Acetylenic GABA in Tardive Dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Plasma norepinephrine and dopamine-beta-hydroxylase activity in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Growth Hormone Responses to Apomorphine HCl in Schizophrenic Patients on Drug Holidays and at Relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Responses of prolactin and growth hormone to L-tryptophan infusion: effects in normal subjects and schizophrenic patients receiving neuroleptics.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

The activities of brain dopamine-?-hydroxylase and catechol-O-methyl transferase in schizophrenics and controls

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Molecular pathology of schizophrenia: more than one disease process?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Monoamine Mechanisms in Chronic Schizophrenia: Post-Mortem Neurochemical Findings

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Letter: Bacloffen in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Increased whole blood serotonin concentrations in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

The Genain Quadruplets 25 years later: a diagnostic and biochemical followup.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Norepinephrine in Chronic Paranoid Schizophrenia: Above-Normal Levels in Limbic Forebrain

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Blood and urinary serotonin and 5-hydroxyindole acetic acid levels in schizophrenic patients and normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Blood tryptophan metabolism in chronic schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Clonidine treatment of schizophrenia. Double-blind comparison to placebo and neuroleptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

The Interaction Between GABA and Dopamine: Implications for Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Elevated blood serotonin concentrations in unmediated chronic schizophrenic patients: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

CSF monoamine metabolites in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Cerebrospinal fluid concentrations of free GABA in schizophrenia: no changes after haloperidol treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Exploration of Affective Illness

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Noradrenergic Overactivity in Chronic Schizophrenia: Evidence Based on Cerebrospinal Fluid Noradrenaline and Cyclic Nucleotide Concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Propranolol in schizophrenia. Clinical, metabolic, and pharmacological findings

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

gamma-Aminobutyric acid in human cerebrospinal fluid: normal values

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Prazosin, a specific alpha1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Brain catecholamines in schizophrenia -- a good case for noradrenaline

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Daily patterns of serotonin uptake in platelets from psychiatric patients and control volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Central noradrenergic function in man: vanillylmandelic acid in CSF

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Diazepam in schizophrenia: a preliminary double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Platelet serotonin concentration and monoamine oxidase activity in unmedicated chronic schizophrenic and in schizoaffective patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Brain tryptophan metabolism in schizophrenia: A post mortem study of metabolites on the serotonin and kynurenine pathways in schizophrenic and control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Dopaminergic mechanisms and cognitive deficit in schizophrenia. A neurobiological model

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Antimanic effect of clonidine

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

alpha-Adrenergic receptor function in schizophrenia. Receptor number, cyclic adenosine monophosphate production, adenylate cyclase activity, and effect of drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Reduced cyclic AMP production in the blood platelets from schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Plasma glutamate decarboxylase activity in neuropsychiatry

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Relationship between CSF noradrenaline levels, C-EEG indicators of activation and psychosis ratings in drug-free schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

24-hour plasma levels of prolactin, cortisol, growth hormone and catecholamines in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Psychiatric illness in first-degree relatives of schizophrenic and surgical control patients. A family study using DSM-III criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Effects of acute haloperidol on the gamma-aminobutyric acid system in rat striatum and substantia nigra

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

The effect of propranolol on CSF amine metabolites in psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Chaotic behavior in dopamine neurodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Serotonin and schizophrenia: correlations between serotonergic activity and schizophrenic motor behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

On certain psychopharmacological and physiological differences between schizophrenic and normal persons

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Chronic Haloperidol Administration Enhances the γ-Aminobutyric Acid Level in the Rat Striatum without Altering the Glutamate Level

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Cerebrospinal fluid GABA levels in various neurological and psychiatric diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Schizophrenia: elevated cerebrospinal fluid norepinephrine

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Clonidine-induced growth hormone secretion in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Pharmacomanometric Studies of Colonic Motility as a Guide to the Chemotherapy of Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Acute high-dose parenteral haloperidol treatment of psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Gamma-Aminobutyric Acid (GABA) in the CSF of Schizophrenic Patients Before and After Neuroleptic Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Reliability of Norepinephrine and Major Monoamine Metabolite Measurements in CSF of Schizophrenic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

γ‐Aminobutyric Acid Concentration in Cerebrospinal Fluid in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Turnover times of gamma-aminobutyric acid and acetylcholine in nucleus caudatus, nucleus accumbens, globus pallidus and substantia nigra: effects of repeated administration of haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Predicting Drug-Free Improvement in Schizophrenic Psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Serum dopamine-beta-hydroxylase in psychiatric patients and normals. Effect of d-amphetamine and haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Low plasma dopamine-ß-hydroxylase in demented schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Effects of clonidine on central and peripheral catecholamine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Effect of clonidine on growth hormone release in psychiatric patients and controls

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Hormones, dopamine receptors and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Serotonin uptake in blood platelets of psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Biological studies of schizoaffective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Serotonin uptake by blood platelets of acute schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Neuroendocrine effects of clonidine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Ethanol specifically potentiates GABA-mediated neurotransmission in feline cerebral cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Plasma GABA levels in psychiatric illness

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Cerebrospinal Fluid Amine Metabolites in Acute Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Propranolol in Schizophrenia: A Double Blind, Placebo Controlled Trial of Propranolol as an Adjunct to Neuroleptic Medication

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Effect of baclofen and haloperidol on gamma-aminobutyric acid and dopamine systems in an animal model of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Cerebral ventricular enlargement in non-genetic schizophrenia: a controlled twin study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Platelet alpha2-adrenergic receptors in schizophrenic patients before and after phenothiazine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Positive and negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

A comparative uptake study of serotonin, dopamine, and norepinephrine by platelets of acute schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Correlation between serotonin uptake and imipramine binding in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

The active uptake of serotonin by platelets of schizophrenic patients and their families: possibility of a genetic marker

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Reduced PGE1 stimulated 3H-cAMP accumulation in platelets from schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Prostaglandins, platelets, and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Covert Transport Dysfunction in the Choroid Plexus as a Possible Cause of Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Catecholamine metabolism in affective disorders. I. Normetanephrine and VMA excretion in depressed patients treated with imipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Gamma-Hydroxybutyrate Treatment of Schizophrenia: A Pilot Study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Relationships in Healthy Volunteers Between Concentrations of Monoamine Metabolites in Cerebrospinal Fluid and Family History of Psychiatric Morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Cerebrospinal fluid MHPG. An assessment of norepinephrine metabolism in affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Fenfluramine and chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Letter: Baclofen in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

ABO blood groups in unipolar and bipolar manic-depressive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Possible Etiology of Schizophrenia: Progressive Damage to the Noradrenergic Reward System by 6-Hydroxydopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

The effect of pimozide on CSF norepinephrine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Impaired Presynaptic Regulation of Norepinephrine in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Schizophrenia: Dopamine β-Hydroxylase Activity and Treatment Response

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

CSF Dopamine β-Hydroxylase in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Differential coupling of GABA-A and GABA-B receptors to the noradrenergic system

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Improvement in Tardive Dyskinesia After Muscimol Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

GABA agonist treatment improves tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Blood platelet 5-hydroxytryptamine levels in psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Cytomegalovirus Antibody in Cerebrospinal Fluid of Schizophrenic Patients Detected by Enzyme Immunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Criteria for subtyping schizophrenia. Clinical differentiation of hebephrenic and paranoid schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

gamma-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

The dopamine hypothesis of schizophrenia revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Impaired noradrenergic transmission in schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

CSF levels of gamma-aminobutyric acid in schizophrenia. Low values in recently ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Dopamine-beta-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Biological suicide research: outcome and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Dopamine-β-Hydroxylase Deficits in the Brains of Schizophrenic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Dopamine β-Hydroxylase Activity in Brains of Chronic Schizophrenic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Propranolol in the control of schizophrenic symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Propranolol as an adjunct to the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

DL-propranolol and chlorpromazine following admission for schizophrenia. A controlled comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Autonomic nervous system activity in acute schizophrenia: I. method and comparison with normal controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Long-term neuroleptic treatment of chronic schizophrenic patients: Clinical and biochemical effects of withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Relationship between norepinephrine in blood and cerebrospinal fluid in the presence of a blood cerebrospinal fluid barrier for norepinephrine

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

Comparison of metoprolol and propranolol in the treatment of akathisia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

GABA and acute psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2808%2960091-4

7 January 2021

10.1016/S0074-7742(08)60091-4

Identifiers

DOI

0 references

1 reference